氢分子医学分享 http://blog.sciencenet.cn/u/孙学军 对氢气生物学效应感兴趣者。可合作研究:sunxjk@hotmail.com 微信 hydrogen_thinker

博文

中风的非药物治疗

已有 5585 次阅读 2009-2-21 16:46 |个人分类:氢气生物学|系统分类:科研笔记| 论文, 氢气, 氢分子医学

该综述是最早讨论氢的生物学效应的论文,从中风的非药物治疗,谈到氧气和氢在中风治疗中的作用价值.

Numerous clinical trials of thrombolytic and neuroprotective
drugs for stroke have been conducted over the last
2 decades. The NINDS trial of intravenous tissue plasminogen
activator remains the most notable success. Intra-arterial
thrombolysis appears promising, but in the absence of phase
III clinical trial data, this approach remains investigational.
Numerous pharmaceutical drugs targeting 1 or more cell
death pathways have failed to show efficacy. Despite failure,
these prior attempts have provided insights regarding critical
issues such as proper clinical trial design and the need for
more rigorous preclinical drug testing in order to improve the
translational leap from bench to bedside.
More recently, accumulating data suggest that “non-drug”
approaches toward stroke therapy might also provide new
opportunities in addition to more traditional pharmaceutical
therapies. As testimony to the growing importance of these
alternate and sometimes complementary methods, there has
been a proliferation of device trials, and the NINDS, through
its key ‘Specialized Program of Translational Research in
Acute Stroke’ [SPOTRIAS] initiative,1 has funded trials of
therapeutic hypothermia, caffeinol, and normobaric hyperoxia,
among others. Although this brief survey focuses on
emerging gas and device therapies for ischemic stroke, it
should be noted that several other ‘non-drug’ approaches,
including physiological strategies (eg, hypothermia, glucose
regulation), and natural agents (eg, albumin, magnesium),
continue to be tested in ongoing trials.

全文

https://wap.sciencenet.cn/blog-41174-216407.html

上一篇:早期目标导向治疗在感染性休克中应用
下一篇:氢分子医学研究学者介绍

1 zhangling

发表评论 评论 (0 个评论)

数据加载中...
扫一扫,分享此博文

Archiver|手机版|科学网 ( 京ICP备07017567号-12 )

GMT+8, 2021-5-11 02:31

Powered by ScienceNet.cn

Copyright © 2007- 中国科学报社

返回顶部